Milnacipran: a unique antidepressant?

References

• BauerMBschorTPfennigAWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary CareWorld J Biol Psychiatry2007826710417455102
   PubMed Web of Science ®Google Scholar
• NuttDJRelationship of neurotransmitters to the symptoms of major depressive disorderJ Clin Psychiatry200869Suppl E14718494537
   PubMed Web of Science ®Google Scholar
• GillmanPKTricyclic antidepressant pharmacology and therapeutic drug interactions updatedBr J Pharmacol2007151673774817471183
   PubMed Web of Science ®Google Scholar
• KasperSZoharJSteinDJDecision-Making in PsychopharmacologyLondonMartin Dunitz2002
   Google Scholar
• KoenigAMThaseMEFirst-line pharmacotherapies for depression – what is the best choicePol Arch Med Wewn200911978478486
   Web of Science ®Google Scholar
• MoretCCharveronMFinbergJPBiochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drugNeuropharmacology198524121112193005901
   PubMed Web of Science ®Google Scholar
• MoretCIsaacMBrileyMProblems associated with long-term treatment with selective serotonin reuptake inhibitorsJ Psychopharmacol20092396797418635702
   PubMed Web of Science ®Google Scholar
• ArrollBMacgillivraySOgstonSEfficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysisAnn Fam Med20053544945616189062
   PubMed Web of Science ®Google Scholar
• AndersonIMSelective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerabilityJ Affect Disord2000581193610760555
   PubMed Web of Science ®Google Scholar
• NuttDDemyttenaereKJankaZThe other face of depression, reduced positive affect: The role of catecholamines in causation and cureJ Psychopharmacol200721546147117050654
   PubMed Web of Science ®Google Scholar
• StahlSMGradyMMMoretCBrileyMSNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressantsCNS Spectr200510973274716142213
   PubMed Web of Science ®Google Scholar
• VaishnaviSNNemeroffCBPlottSJMilnacipran: A comparative analysis of human monoamine uptake and transporter binding affinityBiol Psychiatry200455332032214744476
   PubMed Web of Science ®Google Scholar
• MongeauRWeissMde MontignyCBlierPEffect of acute, short-and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neuronsNeuropharmacology1998379059189776386
   PubMed Web of Science ®Google Scholar
• MuneokaKShirayamaYTakigawaMShiodaSBrain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in ratsNeurochem Res20093454255518751896
   PubMed Web of Science ®Google Scholar
• PuozzoCLeonardBEPharmacokinetics of milnacipran in comparison with other antidepressantsInt Clin Psychopharmacol199611Suppl 415278923123
   PubMed Web of Science ®Google Scholar
• Division of Clinical Pharmacology, School of Medicine, Indiana University Schhol of MedicineP450 Drug Interaction Table Available from: http://medicine.iupui.edu/clinpharm/ddis/table.aspAccessed on May 25, 2010
   Google Scholar
• ParisBLOgilvieBWScheinkoenigJAIn vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipranDrug Metab Dispos200937102045205419608694
   PubMed Web of Science ®Google Scholar
• RosenRCLaneRMMenzaMEffects of SSRIs on sexual function: A critical reviewJ Clin Psychopharmacol19991967859934946
   PubMed Web of Science ®Google Scholar
• KeltnerNLMcAfeeKMTaylorCLMechanisms and treatments of SSRI-induced sexual dysfunctionPerspect Psychiatr Care20023811111612385082
   PubMed Web of Science ®Google Scholar
• ClaytonAHPradkoJFCroftHAPrevalence of sexual dysfunction among newer antidepressantsJ Clin Psychiatry20026335736612000211
   PubMed Web of Science ®Google Scholar
• RaskinJGoldsteinDJMallinckrodtCHFergusonMBDuloxetine in the long-term treatment of major depressive disorderJ Clin Psychiatry2003641237124414658974
   PubMed Web of Science ®Google Scholar
• DetkeMJWiltseCGMallinckrodtCHDuloxetine in the acute and long-term treatment of major depressive disorder: A placebo-and paroxetine-controlled trialEur Neuropsychopharmacol20041445747015589385
   PubMed Web of Science ®Google Scholar
• BaldwinDMorenoRABrileyMResolution of sexual dysfunction during acute treatment of major depression with milnacipranHum Psychopharmacol200823652753218536065
   PubMed Web of Science ®Google Scholar
• MichelsonDFavaMAmsterdamJInterruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trialBr J Psychiatry200017636336810827885
   PubMed Web of Science ®Google Scholar
• PinzaniVGiniesERobertLVenlafaxine withdrawal syndrome: Report of six cases and review of the literatureRev Med Interne200021328228410763190
   PubMed Web of Science ®Google Scholar
• PerahiaDGKajdaszDKDesaiahDHaddadPMSymptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorderJ Affect Disord2005891320721216169088
   PubMed Web of Science ®Google Scholar
• VandelPSechterDWeillerPost-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetineHum Psychopharmacol200419858558615570574
   PubMed Web of Science ®Google Scholar
• Ness-AbramofRApovianCMDrug-induced weight gainDrugs Today (Barc)20054154755516234878
   PubMed Web of Science ®Google Scholar
• Pierre Fabre Médicament – data on file.
   Google Scholar
• KasperSPletanYSollesATournouxAComparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial resultsInt Clin Psychopharmacol199611Suppl 435398923125
   PubMed Web of Science ®Google Scholar
• Lopez-IborJGuelfiJDPletanYMilnacipran and selective serotonin reuptake inhibitors in major depressionInt Clin Psychopharmacol199611Suppl 441468923126
   PubMed Web of Science ®Google Scholar
• SechterDVandelPWeillerEA comparative study of milnacipran and paroxetine in outpatients with major depressionJ Affect Disord20048323233236
   Web of Science ®Google Scholar
• ClercGMilnacipran/Fluvoxamine Study GroupAntidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamineInt Clin Psychopharmacol2001163145151
   PubMed Web of Science ®Google Scholar
• MontesJMFerrandoLSaiz-RuizJRemission in major depression with two antidepressant mechanisms: Results from a naturalistic studyJ Affect Disord2004791322923415023475
   PubMed Web of Science ®Google Scholar
• LiGYUekiHYamamotoYYamadaSAssociation between the scores on the general health questionnaire-28 and the saliva levels of 3-methoxy-4-hydroxyphenylglycol in normal volunteersBiol Psychol200673220921116472905
   PubMed Web of Science ®Google Scholar
• FergusonJMMendelsJSchwartGEEffects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depressionInt Clin Psychopharmacol2002172455111890185
   PubMed Web of Science ®Google Scholar
• PapakostasGIFavaMA meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorderEur Neuropsychopharmacol2007171323616762534
   PubMed Web of Science ®Google Scholar
• AnsseauMPapartPTroisfontainesBControlled comparison of milnacipran and fluoxetine in major depressionPsychopharmacology (Berl)199411411311377846195
   PubMed Web of Science ®Google Scholar
• AnsseauMvon FrenckellRGérardMAInterest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamineEur Neuropsychopharmacol1991121131211821700
   PubMedGoogle Scholar
• GuelfiJDAnsseauMCorrubleEA double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatientsInt Clin Psychopharmacol19981331211289690979
   PubMed Web of Science ®Google Scholar
• LeeMSHamBJKeeBSComparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depressionCurr Med Res Opin20052191369137516197655
   PubMed Web of Science ®Google Scholar
• MontgomerySABaldwinDSBlierPWhich antidepressants have demonstrated superior efficacy? A review of the evidenceInt Clin Psychopharmacol200722632332917917550
   PubMed Web of Science ®Google Scholar
• MansuyLAntidepressant therapy with milnacipran and venlafaxineNeuropsychiatric Disease Treatment2010this supplement
   Google Scholar
• PapakostasGIThaseMEFavaMAre antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsBiol Psychiatry200762111217122717588546
   PubMed Web of Science ®Google Scholar
• SettleECJrAntidepressant drugs: Disturbing and potentially dangerous adverse effectsJ Clin Psychiatry199859Suppl 1625309796863
   PubMed Web of Science ®Google Scholar
• MazurJEDotyJDKrygielASFatality related to a 30-g venlafaxine overdosePharmacotherapy200323121668167214695048
   PubMed Web of Science ®Google Scholar
• BuckleyNAMcManusPRFatal toxicity of serotoninergic and other antidepressant drugs: Analysis of United Kingdom mortality dataBMJ200232573761332133312468481
   PubMed Web of Science ®Google Scholar
• CheetaSSchifanoFOyefesoAAntidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000Br J Psychiatry2004184414714702226
   PubMed Web of Science ®Google Scholar
• MontgomerySAProstJFSollesABrileyMEfficacy and tolerability of milnacipran: An overviewInt Clin Psychopharmacol199611Suppl 447518923127
   PubMed Web of Science ®Google Scholar
• AngstJCourse of mood disorders: A challenge to psychopharmacologyClin Neuropharmacol199215Suppl 1 Pt A444445
   Google Scholar
• MajMVeltroFPirozziRPattern of recurrence of illness after recovery from an episode of major depression: A prospective studyAm J Psychiatry199214967958001590496
   PubMed Web of Science ®Google Scholar
• RouillonFWarnerBPezousNMilnacipran efficacy in the prevention of recurrent depression: A 12-month placebo-controlled studyInt Clin Psychopharmacol200015313314010870871
   PubMed Web of Science ®Google Scholar
• DooganDPCaillardVSertraline in the prevention of depressionBr J Psychiatry19921602172221540762
   PubMed Web of Science ®Google Scholar
• MontgomerySADunbarGParoxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depressionInt Clin Psychopharmacol1993831891958263317
   PubMed Web of Science ®Google Scholar
• KochSHemrick-LueckeSKThompsonLKComparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in ratsNeuropharmacology200345793594414573386
   PubMed Web of Science ®Google Scholar
• DeecherDCBeyerCEJohnstonGDesvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitorJ Pharmacol Exp Ther2006318265766516675639
   PubMed Web of Science ®Google Scholar